FDA Fast-Tracks Moderna-Merck mRNA Cancer Vaccine After Phase 3 Melanoma Trial Shows 65% Recurrence Drop

The US FDA has fast-tracked the Moderna-Merck personalized mRNA cancer vaccine after Phase 3 trials showed a 65% drop in...